$11.49
Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?
How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet
Overview
52-week range
$3.89
$36
23% of range
Avg surprise (last 3)
+2.6%
Avg reaction (last 2)
-3.8%
0% positive
Latest IV / EM
129%
EM ±29.6% · $11 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.52 | $-0.52 | 0.0% | -44.4% | -6.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.49 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.51 | $-0.43 | -18.6% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.36 | $-0.49 | +26.5% | — | -1.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.60 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.54 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.56 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.48 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.49 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.53 | -$0.51 | -3.9% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-58M | — | $-46M | $-48M | $-35M | — | $-38M | $-34M |
| Net income | $-53M | — | $-42M | $-44M | $-30M | — | $-35M | $-30M |
| EPS (diluted) | $-0.52 | — | $-0.49 | $-0.51 | $-0.36 | — | $-0.60 | $-0.54 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $53M | $48M | $35M | $52M | $51M | $139M | $36M | $17M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $513M | $515M | $334M | $368M | $397M | $438M | $218M | $242M |
| Total assets | $531M | $533M | $352M | $382M | $410M | $451M | $230M | $255M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $50M | $55M | $45M | $37M | $26M | $42M | $31M | $27M |
| Total equity | $480M | $479M | $307M | $345M | $383M | $409M | $199M | $227M |